caa a22 4500 445810394 CHVBK 20180317145209.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1007/s00415-010-5863-2 doi (NATIONALLICENCE)springer-10.1007/s00415-010-5863-2 Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis [Elektronische Daten] [M. Axelsson, C. Malmeström, S. Nilsson, S. Haghighi, L. Rosengren, J. Lycke] The major intermediate cytoskeletal protein of astrocytes, glial fibrillary acidic protein (GFAP), and that of axons, neurofilament light protein (NFL), may both be released into the cerebrospinal fluid (CSF) during pathological processes in the central nervous system (CNS). We investigated GFAP and NFL levels in CSF as possible biomarkers for progression in multiple sclerosis (MS). Patients with relapsing-remitting MS (RRMS, n=15) or secondary progressive MS (SPMS, n=10) and healthy control subjects (n=28) were examined twice with an interval of 8-10years apart. Neurological deficits were scored with the Expanded Disability Status Scale (EDSS). GFAP and NFL levels were determined in CSF by enzyme-linked immunosorbent assay (ELISA). GFAP levels and NFL levels correlated with age (r and r s=0.50, p=0.006). Adjusting for age, MS patients had increased GFAP levels compared with controls (p=0.03) and GFAP levels correlated with neurological disability (EDSS, r=0.51, p<0.05) and disease progression [Multiple Sclerosis Severity Score (MSSS), r=0.47, p<0.05]. The mean annual increase of GFAP was 6.5ng/L for controls, 8.1ng/L for RRMS patients, and 18.9ng/L for SPMS patients. GFAP level at the first examination had predictive value for neurological disability 8-10years later (EDSS, r=0.45, p<0.05) but not for EDSS increase between the examinations. NFL levels were not significantly increased in MS patients compared with controls and had no relationship to disability or progression and no prognostic value for disability development. GFAP, a marker for astrogliosis, is a potential biomarker for MS progression and may have a role in clinical trials for assessing the impact of therapies on MS progression. Springer-Verlag, 2010 Multiple sclerosis nationallicence Glial fibrillary acidic protein nationallicence Neurofilament light protein nationallicence Cerebrospinal fluid nationallicence Biomarker nationallicence Neurodegeneration nationallicence Axelsson M. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut Malmeström C. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut Nilsson S. Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden aut Haghighi S. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut Rosengren L. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut Lycke J. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut Journal of Neurology Springer-Verlag 258/5(2011-05-01), 882-888 0340-5354 258:5<882 2011 258 415 https://doi.org/10.1007/s00415-010-5863-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-010-5863-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Axelsson M. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut NATIONALLICENCE 700 1- Malmeström C. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut NATIONALLICENCE 700 1- Nilsson S. Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden aut NATIONALLICENCE 700 1- Haghighi S. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut NATIONALLICENCE 700 1- Rosengren L. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut NATIONALLICENCE 700 1- Lycke J. Department of Neurosciences, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Gothenburg University, 413 45, Gothenburg, Sweden aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/5(2011-05-01), 882-888 0340-5354 258:5<882 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer